Dr. Laura Dember  has more than 20 years of experience as a general nephrologist and has internationally-recognized expertise in the systemic amyloidoses, a group of rare disorders that often affect the kidneys. She has been involved in the development of novel treatments for AL and AA amyloidosis, and is a member of the University of Pennsylvania multidisciplinary amyloidosis program that evaluates and treats patients with all types of amyloidosis and paraprotein disorders.

Dr. Dember is a Deputy Editor of the American Journal of Kidney Diseases and has served on multiple NIH grant review panels and committees of the American Society of Nephrology.

Dr. Dember conducts patient-oriented research including mechanistic studies and clinical trials in chronic kidney disease and end-stage renal disease (ESRD). She has particular interests in hemodialysis vascular access and interventions to improve clinical outcomes in end-stage renal disease. Her research is funded by the National Institutes of Health. Dr. Dember is Principal Investigator for the Data Coordinating Center of the NIDDK Hemodialysis Novel Therapies Consortium which is conducting early phase clinical trials targeting ESRD-associated inflammation and cardiovascular disease, and she is the Principal Investigator for the "TiME Trial", a large, pragmatic cluster-randomized clinical trial being conducted through the NIH Health Care Systems Research Collaboratory. The TiME Trial has enrolled more than 7200 participants at 266 dialysis units throughout the United States and uses highly centralized implementation and data collection approaches that leverage the infrastructure and clinical care delivery systems of dialysis provider organizations. Dr. Dember is also a principal investigator for the NIDDK Hemodialysis Fistula Maturation Study -- a multicenter observational cohort study designed to elucidate predictors and mechanisms of arteriovenous fistula maturation, and she is a member of the Scientific and Data Coordinating Center for the NIDDK Chronic Renal Insufficiency Cohort Study.